Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study by 源�湲곗슦
287www.eymj.org
Serum Fibroblast Growth Factor 21 and New-Onset 
Metabolic Syndrome: KoGES-ARIRANG Study 
Jung Ran Choi1, Jang-Young Kim1,2, Il Hwan Park3, Ji Hye Huh2, Ki Woo Kim4, Seung-Kuy Cha5,6,  
Kyu-Sang Park5,6, Joon Hyung Sohn5, Jong Taek Park7, and Sang Baek Koh1,8
1Institute of Genomic Cohort, 2Department of Internal Medicine, 3Department of Thoracic and Cardiovascular Surgery,  
4Department of Pharmacology, 5Mitohormesis Research Center, 6Department of Physiology, 7Department of Anesthesiology and Pain Medicine, 
8Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Purpose: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeo-
stasis and lipid metabolism. Since serum FGF21 level has been implicated as a potential marker for the early identification of 
metabolic syndrome (MetS), we investigated the association between serum FGF21 level and the development of MetS in a pop-
ulation-based prospective study.
Materials and Methods: We conducted a prospective study of 221 randomly sampled adults without MetS from a general popu-
lation-based cohort study who were examined from 2005–2008 (baseline) and from 2008–2011 (follow-up). Baseline serum 
FGF21 levels were analyzed using enzyme-linked immunosorbent assay.
Results: During the average 2.8-year follow-up period, 82 participants (36.6%) developed new-onset MetS. Serum FGF21 levels 
were significantly higher in patients with new-onset MetS than in those without MetS (209.56±226.80 vs. 110.09±81.10, p<0.01). In 
multivariate adjusted models, the odds for MetS development were greater in patients with serum FGF21 levels in the highest 
quartile, compared to those in the lowest quartile (3.84, 95% confidence interval: 1.59–9.28). 
Conclusion: Serum FGF21 level was an independent predictor for new-onset MetS in a population-based prospective study.
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INTRODUCTION 
The fibroblast growth factor (FGF) family consists of 22 mem-
bers with various biological functions, such as cell growth, de-
velopment, angiogenesis, and wound healing.1 Among these 
members, FGF21 is primarily isolated from liver tissue and 
has recently been shown in animal models to have beneficial 
effects on glucose and lipid metabolism and insulin sensitivi-
ty.1,2 In human studies, high serum FGF21 levels have been 
observed in obese participants with insulin resistant states, 
such as dyslipidemia, coronary artery disease, non-alcoholic 
fatty liver disease, and polycystic ovarian syndrome.1,3-5
Since multiple, favorable FGF21 effects on glucose and lipid 
metabolism and insulin sensitivity have been reported, FGF21 
might be a biomarker that influences metabolic syndrome 
(MetS) and type 2 diabetes (T2DM) pathophysiology.3,6 It may 
also be a therapeutic agent for treating diabetes and other 
obesity-related metabolic disorders.5 FGF21 has also been 
shown to be a potent metabolic regulator.5,7-9 In addition, re-
search has shown that increased FGF21 levels are associated 
with MetS in Asian individuals.10,11 Another report showed an 
association between genetic polymorphisms located within 
the FGF21 3’-untranslated region and the incidence of MetS 
in an Asian cohort study.12 
MetS includes impaired glucose regulation, abdominal 
obesity, dyslipidemia, and high blood pressure. It is estimated 
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that approximately one-fourth of the world’s adult population 
suffers from MetS.2 MetS is a significant factor leading to a 
higher risk of cardiovascular disease and T2DM. MetS is dis-
tinguished by an atherogenic dyslipidemia comprising in-
creased very low-density lipoprotein (VLDL), triglycerides (TG), 
decreased high-density lipoprotein (HDL)-cholesterol, and a 
predominance of small dense low-density lipoprotein (LDL) 
particles.13 Additionally, the Korean National Health and Nu-
trition Examination Survey reported the prevalence of MetS to 
account for about one-third of the total Korean population.10,14 
Because serum FGF21 levels have been implicated as a poten-
tial predictor for the early detection of MetS, we investigated 
the correlation between serum FGF21 level and the incidence 
of MetS in a population-based prospective study. However, no 
prior investigations have reported an association between se-
rum FGF21 levels and the incidence of MetS in Korean longi-
tudinal studies. Therefore, we hypothesized that high serum 
FGF21 levels would be a predictor for new-onset MetS. 
MATERIALS AND METHODS
Study population
This prospective study was conducted using data from the Ko-
rean Genome and Epidemiology Study on the Atherosclerosis 
Risk of Rural Areas in the Korean General Population (KoGES-
ARIRANG). We selected 221 random participants from this 
study. The Institutional Review Board of Wonju Christian Hos-
pital approved the study design (IRB No. CR105024). All partici-
pants provided written informed consent to take part in this 
study. Further inclusion criteria included the absence of any 
other disorder or medication known to affect serum FGF21 level. 
The KoGES-ARIRANG included participants from 40–70 
years of age who resided in the Wonju and Pyengchang areas 
of the Republic of Korea. The baseline survey conducted from 
November 2005 to January 2008 included 5178 adults (2127 
men and 3051 women). In the first follow-up survey (April 2008 
to January 2011), 3862 people participated therein (74.6%). 
We randomly selected 259 individuals (6.7%) from these 3862 
patients. We excluded 19 participants who were diagnosed with 
MetS at baseline and 19 participants with incomplete data, 
which left 221 participants without MetS, who comprised the 
final sample (Fig. 1). 
Anthropometric and biochemical measurements
At baseline and follow-up examinations, study participants 
completed a standardized medical history and lifestyle ques-
tionnaire, as well as a comprehensive health examination that 
followed standard procedures. Clinical phenotypes for all 
participants, including weight, height, and waist circumfer-
ence (WC), were assessed using a tape measure on a horizon-
tal plane midway between the inferior margin of the ribs and 
the superior border of the iliac crest (SECA-200, SECA, Ham-
burg, Germany). Systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) were taken twice using a standard mer-
cury sphygmomanometer (Baumanometer, Copiague, NY, 
USA). Participant smoking status was also recorded. 
A venous blood sample was obtained from the study popula-
tions following an overnight fast. Serum aliquots were stored 
at -80oC until ready for further analysis. Fasting glucose was de-
termined using a glucose oxidase-based assay, and fasting in-
sulin was measured using a double-antibody radioimmunoas-
say RIA (Biosource, Belgium). Serum concentrations for LDL 
cholesterol, HDL cholesterol, and TG were analyzed with en-
zymatic methods (Advia 1650, Siemens, Tarrytown, NY, USA). 
Degree of insulin resistance was evaluated using the homeo-
stasis model assessment of insulin resistance (HOMA-IR) as 
follows: fasting insulin (µIU/mL)×fasting plasma glucose (mg/
dL)/405. 
Serum FGF21 levels were assessed with a sandwich enzyme-
linked immunosorbent assay (ELISA) (FGF-21 ELISA Kit, Cat. 
No. AG-45B-5001-KI01; Adipogen, Switzerland) according to 
the manufacturer’s instructions. All of the serum samples were 
assayed in duplicate, and the mean value of the two measure-
ments was used for analysis. A blood sample was obtained from 
the study participants following an overnight fast, and serum 
aliquots were stored at -80°C until ready for further analysis. 
Median FGF21 levels were 113.21 with an interquartile range 
(IQR) of 123.7 (Q3–Q1=177.87–54.17). The ranges for each quar-
tile were Q1 (≤54.17), Q2 (54.17–113.21), Q3 (113.21–177.87), 
and Q4 (≥177.87). 
Endpoint 
In accordance with previous studies,15 MetS was defined as 
the presence of at least three of the following components: 1) 
3862 individuals of KoGES-ARIRANG
New-onset MetS
82 (37.1%)
No MetS
139 (62.9%)
Random sampling
2.8 years follow-up
Excluded  
MetS at baseline (n=19)
Incomplete data (n=19)
Fig. 1. KoGES-ARIRANG study participant flow chart. KoGES-ARIRANG, 
Korean Genome and Epidemiology Study on the Atherosclerosis Risk of 
Rural Areas in the Korean General Population; MetS, metabolic syn-
drome.
259 individuals (6.7% of all participants)
221 individuals
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abdominal obesity or a WC ≥90 cm for men or ≥85 cm for 
women (following the Korean-specific cutoffs for abdominal 
obesity set by the Korean Society of Obesity);16 2) hypertriglyc-
eridemia or a serum TG concentration ≥150 mg/dL (1.69 mmol/
L); 3) low HDL cholesterol or a serum HDL cholesterol concen-
tration <40 mg/dL (1.04 mmol/L) for men or <50 mg/dL (1.29 
mmol/L) for women; 4) high blood pressure, an SBP ≥130 
mm Hg, a DBP ≥85 mm Hg, or treatment with antihyperten-
sive agents; and 5) high fasting glucose, a fasting serum glu-
cose ≥100 mg/dL, or previously diagnosed T2DM.
Statistical analysis 
Multivariate logistic regression was used to assess indepen-
dent associations between baseline FGF21 levels and the pres-
ence of new-onset MetS. We used two models with progressive 
degrees of adjustment. First, we conducted an age- (continu-
ous variable) and gender- (nominal variable: male and female) 
adjusted analysis. We then further adjusted for baseline levels 
of body mass index (BMI, continuous variable), LDL choles-
terol (continuous variable), smoking status (nominal variable: 
current/former/never), and regular exercise (nominal variable: 
yes/no). Results are expressed as odds ratios (ORs) with 95% 
confidence intervals (CIs). All analyses were performed using 
the Statistical Package for the Social Sciences software, version 
21.0 (IBM Corp., Armonk, NY, USA). p-values <0.05 were con-
sidered statistically significant.
RESULTS 
Over 2.8 years of follow-up, 82 (37.1%) new MetS cases were 
diagnosed. Initial BMI, WC, SBP, DBP, fasting glucose, TG, 
LDL, and HOMA-IR were significantly higher, while HDL cho-
lesterol was significantly lower, in those who had developed 
MetS than in those who did not. The mean FGF21 level at base-
line was significantly higher in individuals who developed 
MetS than in those who did not (209.56±226.80 vs. 110.09±81.10, 
p<0.01) (Table 1). Similar associations were observed between 
serum FGF21 level and each MetS component. Furthermore, 
serum FGF21 progressively increased as the number of MetS 
components increased over the follow-up period (all p for 
trend: <0.01) (Table 2).
Multivariate regression models adjusted for baseline BMI, 
LDL cholesterol, smoking, and regular exercise revealed a sig-
nificant association between serum FGF21 levels and the pres-
ence of new-onset MetS (model 2) (Table 3). The OR for MetS 
development was 3.84 (95% CI: 1.59–9.28) for the highest se-
rum FGF21 quartile. Corresponding ORs (95% CI) for high WC, 
low HDL cholesterol, high TG, high blood pressure, and high 
blood glucose were 3.36 (1.15–9.76), 0.89 (0.39−2.06), 1.72 
(0.79−3.74), 1.51 (0.69−3.31), and 2.60 (1.15−5.89), respectively. 
Receiver operating characteristic curves for FGF21 levels were 
drawn to predict the presence of MetS in Korean adults 
(AUC=0.650, p<0.001) (data not shown).
DISCUSSION 
In this prospective study, we investigated whether increases 
in FGF21 are significantly associated with a higher risk of new 
onset MetS (OR: 3.84, 95% CI: 1.59−9.28). We noted a signifi-
cant and progressive elevation in serum FGF21 levels as the 
number of MetS components increased among study partici-
pants over the follow-up period. Therefore, we suggest that 
high serum FGF21 levels might be a diagnostic predictor for 
MetS development. This study may be the first prospective epi-
Table 1. Baseline Characteristics of the Study Population according to New-Onset MetS
Variables No MetS MetS p value*
N (%)      139 (62.9)        82 (37.1)
Sex, male (n, %)        43 (30.9)        30 (36.6)   0.78
Age (yr)     56.9 (7.8)     55.4 (7.9)   0.18
Current smoking (%)        38 (27.7)        14 (17.1)   0.01
Body mass index (kg/m2)   22.94 (2.77)  27.39 (18.53)   0.01
Waist circumference (cm)   82.23 (6.76)   89.53 (7.03) <0.01
Systolic BP (mm Hg) 119.64 (16.32) 129.24 (13.20) <0.01
Diastolic BP (mm Hg)   75.48 (10.42)   82.34 (9.55)   0.01
Fasting glucose (mg/dL)   90.19 (10.47)   99.48 (17.94) <0.01
HDL-cholesterol (mg/dL)   48.86 (11.44)   41.13 (7.35) <0.01
LDL-cholesterol (mg/dL) 103.90 (28.99) 114.44 (36.36)   0.02
Triglycerides (mg/d) 109.90 (28.99) 171.23 (107.34) <0.01
HOMA-IR (units)     1.38 (1.08, 1.77)     1.65 (1.40, 2.12) <0.01*
FGF21 110.09 (81.10) 209.56 (226.80) <0.01
MetS, metabolic syndrome; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin 
resistance; FGF21, fibroblast growth factor 21.
Values are expressed as mean (SD), number (%), or median (25th, 75th percentiles).
*p value from Mann-Whitney U test.
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demiological study to explore the association between serum 
FGF21 level and new-onset MetS in a Korean population.
Many animal and clinical studies have emphasized the role 
of FGF21 in promoting metabolic disease development and 
progression.5 FGF21 was initially identified as a factor that in-
creased glucose uptake in mouse 3T3-L1 and primary human 
adipocytes.5 In general, FGF21 has been found to be a meta-
bolic regulator with potential anti-diabetic effects in studies 
using high throughput screening for agents efficient at increas-
ing glucose uptake by 3T3-L1s.1,2 Recent studies have demon-
strated that FGF21 is up-regulated by peroxisome proliferator-
activated receptor-α (PPARα) in animal and human liver tissue 
and by proliferator-activated receptor-γ (PPARγ) in adipose tis-
sue.1,17-19 FGF21 expression and secretion is induced in the liv-
er during fasting, and fatty acids promote the expression and 
secretion of FGF21 in a PPAR-α-dependent manner.3 Further-
Table 2. Baseline FGF21 according to the Presence or Absence of Components of New-Onset MetS
Variables
FGF21 Ln (FGF21)
Absent Present p value Absent Present p value
MetS 110.09 (81.10) 209.56 (226.80) <0.01 4.36 (1.06) 4.95 (0.98) <0.01
High WC   125.60 (114.27) 195.66 (206.68) <0.01 4.43 (1.11) 4.86 (0.94) <0.01
Low HDL cholesterol   141.87 (157.60) 168.08 (168.04)   0.21 4.52 (1.16) 4.70 (0.95)   0.17
Elevated TG   142.55 (170.47) 178.78 (146.34)   0.09 4.49 (1.12) 4.83 (0.92)   0.02
High blood pressure   141.50 (137.79) 174.77 (193.17)   0.12 4.51 (1.14) 4.75 (0.92)   0.09
Elevated blood glucose   128.01 (109.66) 223.56 (240.01) <0.01 4.41 (1.06) 4.97 (0.97) <0.01
No. of components
0 115.78 (81.27) 4.34 (1.40)
1 100.45 (89.57) 4.22 (0.95)
2 116.33 (68.58) 4.58 (0.60)
≥3   217.01 (218.73) 4.95 (0.98)
p for trend <0.01 <0.01
MetS, metabolic syndrome; WC, waist circumference; HDL, high-density lipoprotein; TG, triglycerides; FGF21, fibroblast growth factor 21.
Values are expressed as means (SD). 
Table 3. ORs for New-Onset MetS and Its Components according to Baseline FGF21
 Variables
FGF21
Quartile 1 Quartile 2 Quartile 3 Quartile 4
No. of new-onset MetS cases (%) 33.9 17.2 44.4 54.9
MetS, OR (95% CI)     
Model 1 1.00 0.35 (0.14–0.85) 1.39 (0.62–3.11) 3.35 (1.50–7.46)
Model 2 1.00 0.37 (0.14–0.94) 1.59 (0.66–3.85) 3.84 (1.59–9.28)
High waist circumference, OR (95% CI)*  
Model 1 1.00 0.95 (0.42–2.12) 1.74 (0.78–3.87) 2.66 (1.22–5.82)
Model 2 1.00 1.24 (0.42–3.58) 2.29 (0.76–6.78) 3.36 (1.15–9.76)
Low HDL cholesterol, OR (95% CI)*  
Model 1 1.00 0.46 (0.20–1.07) 0.65 (0.28–1.51) 0.93 (0.41–2.09)
Model 2 1.00 0.51 (0.22–1.19) 0.72 (0.30–1.72) 0.89 (0.39–2.06)
High TG, OR (95% CI)*  
Model 1 1.00 0.54 (0.23–1.26) 1.62 (0.74–3.52) 1.59 (0.74–3.42)
Model 2 1.00 0.57 (0.24–1.34) 1.68 (0.76–3.70) 1.72 (0.79–3.74)
High blood pressure, OR (95% CI)*  
Model 1 1.00 0.95 (0.44–2.04) 1.24 (0.58–2.63) 1.42 (0.66–3.06)
Model 2 1.00 1.01 (0.46–2.20) 1.13 (0.52–2.45) 1.51 (0.69–3.31)
High blood glucose, OR (95% CI)*  
Model 1 1.00 0.51 (0.19–1.33) 1.81 (0.79–4.15) 2.65 (1.19–5.89)
Model 2 1.00 0.53 (0.20–1.43) 1.80 (0.77–4.22) 2.60 (1.15–5.89)
MetS, metabolic syndrome; OR, odds ratio; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; FGF21, fibroblast 
growth factor 21.
Model 1: adjusted for age and gender; Model 2: Model 1+additionally adjusted with baseline body mass index, LDL cholesterol, smoking, regular exercise.
*Each component of MetS at baseline has been excluded.
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more, research has suggested a prominent synergy between 
FGF21 and the antidiabetic agent rosiglitazone, a PPAR-γ ago-
nist, in stimulating glucose uptake.20 FGF21 signaling is medi-
ated by the FGF receptor and the adapter molecule β-Klotho, 
whose expression is induced during adipogenesis.1,3 FGF21 
has also been demonstrated to enhance pancreatic β-cell func-
tion and survival through the activation of extracellular signal-
related kinase 1/2 and the Akt signaling pathway.21 Conse-
quently, FGF21 signaling has been suggested to influence 
glucose, lipid, cholesterol, and bile acid mechanisms, trans-
forming FGF21 into a plausible candidate that may directly 
affect MetS and T2DM pathophysiology.3,18 Therefore, several 
effects of FGF21 on glucose and lipid metabolism and insulin 
sensitivity have indicated that FGF21 could be used as a thera-
peutic agent for diabetes and other obesity-related MetS con-
ditions.22 
In this prospective study, we investigated elevated serum 
FGF21 levels in patients with MetS in comparison to control 
participants without MetS (Table 1) in a manner that was sim-
ilar to those used in previous studies. Patients with coronary ar-
tery disease demonstrated significantly higher plasma FGF21 
levels, which were positively associated with total serum cho-
lesterol, TG, and HDL levels.23-25 Recent results have shown 
that serum FGF21 levels are independently and significantly 
increased in participants with higher TG levels or a higher SBP 
in Japanese individuals.4 Additionally, serum FGF21 levels were 
significantly associated with SBP: a similar result was also found 
in this study (Table 3). Because factors such as TG and SBP are 
associated with MetS, these reports suggest that serum FGF21 
levels could be a biomarker predicting metabolic disorders re-
lated to MetS.4 Compared to previous cross-sectional observa-
tions, a prospective cohort study similar to this study will likely 
be required to confirm FGF21 level as a predictor for meta-
bolic disorders associated with MetS components, as well as 
MetS itself.8 
Upon logistic regression analysis, participants in the second 
quartile of serum FGF21 had an OR of 0.35 (95% CI: 0.14−0.85, 
p<0.0001) for the association with MetS, compared to partici-
pants in the lowest quartile for serum FGF21 (Model 1) (Table 
3). This OR remained statistically significant even after adjust-
ing for potential confounders; however, this result also dem-
onstrated a negative association between serum FGF21 levels 
and MetS (Table 3). Because previous studies have suggested 
that endoplasmic reticulum (ER) stress in the cell may con-
tribute to obesity-associated metabolic disease and that FGF21 
expression is elevated in obese patients and mouse models of 
obesity, prior studies have investigated the pathophysiological 
function of FGF21 in ER stress and metabolic alterations in 
obese mice.26-28 Recently, Kim, et al.26 observed that FGF21 
plays a crucial role in the adaptive response to ER stress- or 
obesity-induced hepatic metabolic stress, and also demon-
strated that FGF21 induction plays a protective role in obesity-
related ER stress and metabolic aggravation. This might be 
due to the protective effect of increasing FGF21 levels, to a 
certain extent, on MetS, although increased FGF21 might re-
flect FGF21-resistance.29,30 Similar to this study, Bobbert, et al.3 
suggested FGF21 is an independent predictor of MetS and 
T2DM in apparently healthy Caucasians, and these results 
may indicate FGF21 resistance precedes the onset of MetS 
and T2DM. There are some data in cross-sectional human 
studies showing a positive correlation between FGF21 values 
and obesity, T2DM, or MetS. Nevertheless, the pathophysio-
logic effects of FGF21 on glucose lipid metabolism are not 
well understood, especially because initial animal and in vitro 
studies proposed glucose-lowering effects and improved fat 
metabolism. We assumed that lower FGF21 serum expression 
had no role in obesity-related ER stress and metabolic effects; 
therefore, metabolic alterations were likely responsible for 
MetS in participants from the second quartile. However, no 
prior prospective studies have examined the development of 
MetS or performed a quantitative or qualitative analysis of 
FGF21 expression levels. As a result, it was difficult to predict 
the correlation between serum FGF21 level and the incidence 
of MetS in our follow-up cohort. Therefore, based on the results 
of this population-based prospective cohort study, it was rea-
sonable to suggest that alterations in FGF21 level are surro-
gate markers for new-onset MetS. 
This study had some limitations. Results were based on a sin-
gle FGF21 level measurement, which was subject to random 
measurement errors, and may have undervalued correlation 
strength. The sample size was relatively small, and the follow-
up period was short (only 2.8 years). Therefore, we could not 
estimate whether the association between serum FGF21 level 
and new-onset MetS would have been maintained over a lon-
ger period. Our findings may not be generalizable to other pop-
ulations, especially different ethnicities, with higher levels of 
obesity or younger mean age. Additionally, we found no suffi-
cient references to corroborate the association between serum 
FGF21 level and MetS onset found in this study.
In conclusion, this prospective cohort study demonstrated 
that FGF21 may be a significant biomarker predicting the de-
velopment of MetS. MetS is a condition predicting risk of dia-
betes, hypertension, and dyslipidemia, which together be-
come risks of atherosclerotic diseases. MetS has been shown 
to be associated with mitochondrial dysfunction, and FGF21 
signaling has been suggested to influence glucose, lipid, cho-
lesterol and bile acid mechanisms, transforming FGF21 into a 
plausible candidate that may directly affect MetS and T2DM 
pathophysiology. Therefore, FGF21 could potentially be of use 
as a therapeutic agent for diabetes and other obesity-related 
MetS conditions. Future biological mechanism studies should 
investigate MetS pathogenesis with respect to the bioenerget-
ics pathway, including FGF21 signaling, in metabolic regula-
tion. These future studies should provide new insights into the 
role of FGF21 as a biomarker for MetS management and sug-
gest FGF21-based therapies that may effectively treat MetS.  
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